Addex Therapeutics (ADXN) Competitors $9.00 +0.48 (+5.59%) Closing price 10/15/2025 03:57 PM EasternExtended Trading$8.96 -0.04 (-0.39%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADXN vs. MAAQ, RANI, ITRM, TENX, SCYX, XFOR, TAOX, ANVS, XCUR, and AKTXShould you be buying Addex Therapeutics stock or one of its competitors? The main competitors of Addex Therapeutics include Mana Capital Acquisition (MAAQ), Rani Therapeutics (RANI), Iterum Therapeutics (ITRM), Tenax Therapeutics (TENX), SCYNEXIS (SCYX), X4 Pharmaceuticals (XFOR), Synaptogenix (TAOX), Annovis Bio (ANVS), Exicure (XCUR), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Addex Therapeutics vs. Its Competitors Mana Capital Acquisition Rani Therapeutics Iterum Therapeutics Tenax Therapeutics SCYNEXIS X4 Pharmaceuticals Synaptogenix Annovis Bio Exicure Akari Therapeutics Addex Therapeutics (NASDAQ:ADXN) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership. Do insiders and institutionals have more ownership in ADXN or MAAQ? 16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is ADXN or MAAQ more profitable? Addex Therapeutics has a net margin of 3,584.49% compared to Mana Capital Acquisition's net margin of 0.00%. Mana Capital Acquisition's return on equity of 0.00% beat Addex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Addex Therapeutics3,584.49% -68.40% -60.68% Mana Capital Acquisition N/A N/A N/A Does the media favor ADXN or MAAQ? In the previous week, Addex Therapeutics had 4 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 4 mentions for Addex Therapeutics and 0 mentions for Mana Capital Acquisition. Addex Therapeutics' average media sentiment score of 0.95 beat Mana Capital Acquisition's score of 0.00 indicating that Addex Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Addex Therapeutics Positive Mana Capital Acquisition Neutral Do analysts rate ADXN or MAAQ? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Addex Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, ADXN or MAAQ? Addex Therapeutics has higher revenue and earnings than Mana Capital Acquisition. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAddex Therapeutics$460K20.73$8.02M-$0.34-26.46Mana Capital AcquisitionN/AN/AN/AN/AN/A SummaryAddex Therapeutics beats Mana Capital Acquisition on 6 of the 9 factors compared between the two stocks. Get Addex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADXN vs. The Competition Export to ExcelMetricAddex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.03M$2.96B$6.10B$10.46BDividend YieldN/A57.77%5.73%4.77%P/E Ratio-26.4622.7985.5227.36Price / Sales20.73778.33609.44137.64Price / CashN/A172.6337.4661.86Price / Book0.875.5112.396.81Net Income$8.02M$33.06M$3.32B$276.80M7 Day Performance-0.76%0.23%0.57%0.42%1 Month Performance-3.99%14.73%10.53%7.86%1 Year Performance-14.73%-1.42%72.40%41.24% Addex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADXNAddex Therapeutics0.4688 of 5 stars$9.00+5.6%N/A-13.9%$9.03M$460K-26.4630News CoverageAnalyst ForecastMAAQMana Capital AcquisitionN/A$4.44+6.9%N/A+1,996.2%$36.03MN/A0.001Gap DownRANIRani Therapeutics3.3299 of 5 stars$0.48+3.4%$7.33+1,413.9%-76.9%$34.81M$1.03M-0.53110ITRMIterum Therapeutics1.8964 of 5 stars$0.73+0.0%$9.00+1,132.9%-27.7%$34.43MN/A-0.8610TENXTenax Therapeutics2.6349 of 5 stars$7.51+1.3%$18.00+139.7%+89.2%$34.25MN/A-8.169News CoverageAnalyst ForecastSCYXSCYNEXIS0.654 of 5 stars$0.81+0.0%N/A-46.4%$34.06M$3.75M-2.0360News CoverageAnalyst ForecastGap UpHigh Trading VolumeXFORX4 Pharmaceuticals4.2632 of 5 stars$2.97-2.9%$34.17+1,050.4%-82.9%$33.89M$2.56M-0.2080TAOXSynaptogenix0.1949 of 5 stars$9.60+0.6%N/AN/A$33.50MN/A-0.484Gap UpANVSAnnovis Bio2.898 of 5 stars$1.68+1.2%$17.33+931.7%-77.3%$32.74MN/A-0.823News CoverageGap UpXCURExicure1.7432 of 5 stars$5.10-0.8%N/A+126.2%$32.22MN/A-1.3150AKTXAkari Therapeutics3.1428 of 5 stars$0.98+4.0%$3.30+236.7%-67.9%$31.97MN/A0.009News CoverageGap Down Related Companies and Tools Related Companies Mana Capital Acquisition Alternatives Rani Therapeutics Alternatives Iterum Therapeutics Alternatives Tenax Therapeutics Alternatives SCYNEXIS Alternatives X4 Pharmaceuticals Alternatives Synaptogenix Alternatives Annovis Bio Alternatives Exicure Alternatives Akari Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADXN) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s “Smart Dollar” just went mainstream"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
